Key Highlights
- Michael Dougherty resigns as CFO to join the energy industry in the Pacific Northwest.
- J. Michael Edwards appointed as interim CFO following Dougherty’s departure.
- Dougherty to assist in transition until September 15, 2024.
Source: Business Wire
Notable Quotes
- “We expect a seamless transition given the strong team and financial processes that Mike Dougherty has put in place and Michael Edwards’ extensive experience as bioAffinity’s previous CFO.” – Maria Zannes, President and CEO at bioAffinity Technologies
- “I’m proud of our accomplishments and leave with mixed emotions for this unexpected opportunity in the Pacific Northwest closer to home and family.” – Michael Dougherty, outgoing CFO at bioAffinity Technologies
SoHC's Take
The departure of Michael Dougherty as CFO marks a significant transition for bioAffinity Technologies, especially as the company continues to advance its noninvasive lung cancer diagnostic, CyPath® Lung. However, with J. Michael Edwards stepping in as interim CFO, bioAffinity benefits from a seasoned leader with deep knowledge of the company’s financial operations, ensuring continuity. This strategic move may also bring fresh perspectives and stability as bioAffinity navigates the evolving biotechnology landscape and its ambitious goals in cancer diagnostics.
